Trials / Terminated
TerminatedNCT01134835
PPAR-gamma: a Novel Therapeutic Target for Asthma?
PPAR-gamma: a Novel Therapeutic Target in Asthma?
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- University of Nottingham · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To test the hypothesis that stimulation of PPAR-γ receptors has a therapeutic role in the treatment of asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | placebo | placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks |
| DRUG | IMP Pioglitozone | Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks. |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2012-02-01
- Completion
- 2012-07-01
- First posted
- 2010-06-02
- Last updated
- 2015-12-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01134835. Inclusion in this directory is not an endorsement.